Neuro Sigma Inc
NeuroSigma Inc., based in Los Angeles, CA, is at the forefront of innovative medical technology, having developed the Monarch eTNS System, the first FDA-cleared device for treating pediatric ADHD in children aged 7 to 12 who are not currently on prescription medications. The device, which requires a prescription, is intended for use at home under caregiver supervision during sleep, offering a non-invasive treatment option for ADHD symptoms.
The Monarch eTNS System has shown a favorable safety profile, with common side effects including drowsiness and increased appetite, but no serious adverse events reported. NeuroSigma continues to expand its reach and applications through ongoing clinical trials and patent developments, solidifying its commitment to addressing neurodevelopmental disorders.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.